# US 2016/0354376 A1 · Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354376 A1
- Document ID: US20160354376A1
- Status: Published application
- Kind: A1
- Application number: 15/028,947
- Filed: 2014-10-17
- Published: 2016-12-08
- Earliest claimed: 2013-10-17
- Assignees: Sartar Therapeutics Ltd
- Applicants: Sartar Therapeutics Ltd
- Inventors: Harri Sihto; Olli-Pekka Pulkka; Olli Kallioniemi; Heikki Joensuu
- Web page: https://patentgrep.com/patent/US20160354376A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/573: for enzymes or isoenzymes
- G01N 33/5753: of the stomach or small intestine
- G01N 2333/916: acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention is related to a composition comprising a phosphodiesterase inhibitor, such as anagrelide or a salt thereof, for use in the treatment of a solid tumor, such as gastrointestinal stromal tumor (GIST) or a liposarcoma, which express phosphodiesterase 3 enzymes, in a human patient.

## Claims

### Claim at position 1

-27. (canceled)

### Claim 28

A method for treatment of a phosphodiesterase 3A and/or phosphodiesterase 3B enzyme expressing solid tumor in a human patient, wherein a pharmaceutically effective amount of a composition comprising anagrelide or a salt thereof is administered to a patient in need of such treatment.

### Claim 29 (depends on 28)

The method according to claim 28, wherein said solid tumor is detected to comprise cells displaying high expression of phosphodiesterase 3A and/or phosphodiesterase 3B enzyme mRNA or protein compared to healthy control tissue.

### Claim 30 (depends on 28)

The method according to claim 28, wherein said solid tumor is gastrointestinal stromal tumor, GIST, or a liposarcoma.

### Claim 31 (depends on 28)

The method according to claim 28, wherein said composition comprises anagrelide hydrochloride.

### Claim 32 (depends on 28)

The method according to claim 28, wherein said composition further comprises a tyrosine kinase inhibitor.

### Claim 33 (depends on 32)

The method according to claim 32, wherein said tyrosine kinase inhibitor is specific for KIT and platelet-derived growth factor receptor and is selected from the group consisting of nilotinib, sunitinib, regorafenib, imatinib, imatinib mesylate, masitinib, dovitinib, ponatinib, pazopanib, sorafenib, dasatinib, vatalanib and crenolanib.

### Claim 34 (depends on 28)

The method according to claim 28, wherein said composition is administered to said patient, simultaneously or sequentially, in combination with a composition comprising a tyrosine kinase inhibitor.

### Claim 35 (depends on 28)

The method according to claim 28, wherein said composition is a pharmaceutical composition comprising pharmaceutically acceptable buffer, carrier or adjuvant.

### Claim 36 (depends on 35)

The method according to claim 35, wherein said pharmaceutical composition is formulated for sustained-release, delayed-release, or timed-release, or said pharmaceutical composition is a blend of sustained-release and immediate-release formulations.

### Claim 37

A method for treatment of gastrointestinal stromal tumor (GIST) or liposarcomas in a human patient, wherein a pharmaceutically effective amount of a composition comprising a phosphodiesterase 3 inhibitor is administered to a patient in need of such treatment.

### Claim 38 (depends on 37)

The method according to claim 37, wherein said solid tumor is detected to comprise cells displaying high expression of phosphodiesterase 3A and/or phosphodiesterase 3B enzyme mRNA or protein compared to healthy control tissue.

### Claim 39 (depends on 37)

The method according to claim 37, wherein said composition further comprises a tyrosine kinase inhibitor.

### Claim 40 (depends on 39)

The method according to claim 39, wherein said tyrosine kinase inhibitor is specific for KIT and platelet-derived growth factor receptor and is selected from the group consisting of nilotinib, sunitinib, regorafenib, imatinib, imatinib mesylate, masitinib, dovitinib, ponatinib, pazopanib, sorafenib, dasatinib, vatalanib and crenolanib.

### Claim 41 (depends on 37)

The method according to claim 37, wherein said composition is administered to said patient, simultaneously or sequentially, in combination with a composition comprising a tyrosine kinase inhibitor.

### Claim 42 (depends on 37)

The method according to claim 37, wherein said composition is a pharmaceutical composition comprising pharmaceutically acceptable buffer, carrier or adjuvant.

### Claim 43 (depends on 42)

The method according to claim 42, wherein said pharmaceutical composition is formulated for sustained-release, delayed-release, or timed-release, or the composition is a blend of sustained-release and immediate-release.
